:Teniloxazine

{{Short description|Chemical compound}}

{{Drugbox

| Verifiedfields = changed

| verifiedrevid = 470601949

| IUPAC_name = 2-{[2-(thiophen-2-ylmethyl)phenoxy]methyl}morpholine

| image = Teniloxazine.svg

| width = 215

| CAS_number_Ref = {{cascite|changed|??}}

| CAS_number = 62473-79-4

| CAS_supplemental =
62473-80-7 (maleate)

| ATC_prefix = None

| ATC_suffix =

| UNII_Ref = {{fdacite|correct|FDA}}

| UNII = 95Q6WNP25P

| PubChem = 119114

| ChemSpiderID = 106426

| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}

| ChEMBL = 2105438

| C = 16 | H = 19 | N = 1 | O = 2 | S = 1

| smiles = O1CCNCC1COc2ccccc2Cc3sccc3

| synonyms = Y-8894

| StdInChI_Ref = {{stdinchicite|correct|chemspider}}

| StdInChI = 1S/C16H19NO2S/c1-2-6-16(19-12-14-11-17-7-8-18-14)13(4-1)10-15-5-3-9-20-15/h1-6,9,14,17H,7-8,10-12H2

| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}}

| StdInChIKey = OILWWIVKIDXCIB-UHFFFAOYSA-N

| bioavailability =

| protein_bound =

| metabolism =

| elimination_half-life =

| excretion =

| pregnancy_category =

| legal_status = Rx-only

| routes_of_administration = Oral

}}

Teniloxazine (Lucelan, Metatone), also known as sufoxazine and sulfoxazine, is a drug which is marketed in Japan.{{cite book | vauthors = Ganellin CR, Triggle DJ, Macdonald F | title = Dictionary of pharmacological agents | url = https://books.google.com/books?id=A0THacd46ZsC&pg=PA1905 | access-date=27 October 2011 | year = 1997 | publisher = CRC Press | isbn = 978-0-412-46630-4 | pages = 1905}} Though initially investigated as a neuroprotective and nootropic agent for the treatment of cerebrovascular insufficiency in the 1980s,{{cite journal |vauthors=Anami K, Yamamoto Y, Setoguchi M | title = [Pharmacological studies on sufoxazine (Y-8894). (I) Effects on experimental amnesia in mice] | language = ja | journal = Nihon Yakurigaku Zasshi. Folia Pharmacologica Japonica | volume = 85 | issue = 2 | pages = 71–7 |date=February 1985 | pmid = 2859238 | doi = 10.1254/fpj.85.71| doi-access = free }}{{cite journal |vauthors=Izumi N, Yasuda H | title = [Pharmacological studies on sufoxazine (Y-8894). (II). Anti-anoxic effect] | language = ja | journal = Nihon Yakurigaku Zasshi. Folia Pharmacologica Japonica | volume = 86 | issue = 4 | pages = 323–8 |date=October 1985 | pmid = 4085932 | doi = 10.1254/fpj.86.323| doi-access = free }}{{cite journal |vauthors=Usa T, Morimoto Y, Fukuda T, Anami K, Setoguchi M, Maruyama Y | title = [Pharmacological studies on Y-8894. (III). Its effect on the abnormal electrocorticogram induced by destruction of the internal capsule] | language = ja | journal = Nihon Yakurigaku Zasshi. Folia Pharmacologica Japonica | volume = 88 | issue = 4 | pages = 289–97 |date=October 1986 | pmid = 3491778 | doi = 10.1254/fpj.88.289| doi-access = free }}{{cite journal |vauthors=Yasuda H, Izumi N, Nakanishi M, Anami K, Maruyama Y | title = [Pharmacological studies on Y-8894. (IV). Ameliorative effect on a cerebral energy metabolism disorder induced by KCN] | language = ja | journal = Nihon Yakurigaku Zasshi. Folia Pharmacologica Japonica | volume = 88 | issue = 5 | pages = 363–7 |date=November 1986 | pmid = 3817653 | doi = 10.1254/fpj.88.363| doi-access = free }}{{cite journal |vauthors=Anami K, Yamamoto Y, Setoguchi M, Maruyama Y | title = [Pharmacological studies on Y-8894. (V) Effect on learning and memory in intact and experimentally amnesic rats] | language = ja | journal = Nihon Yakurigaku Zasshi. Folia Pharmacologica Japonica | volume = 89 | issue = 3 | pages = 145–53 |date=March 1987 | pmid = 2884174 | doi = 10.1254/fpj.89.145| doi-access = free }}{{cite journal |vauthors=Setoguchi M, Takehara S, Sakamori M, Anami K, Maruyama Y | title = [Pharmacological studies on Y-8894 (VI). The effect on monoamine uptake and turnover in mouse brain] | language = ja | journal = Nihon Yakurigaku Zasshi. Folia Pharmacologica Japonica | volume = 90 | issue = 1 | pages = 41–9 |date=July 1987 | pmid = 2443434 | doi = 10.1254/fpj.90.41| doi-access = free }}{{cite journal |vauthors=Yasumatsu H, Yamamoto Y, Takamuku H, etal | title = [Pharmacological studies on Y-8894. (VII). Effects on transient cerebral ischemia-induced amnesia in rats] | language = ja | journal = Nihon Yakurigaku Zasshi. Folia Pharmacologica Japonica | volume = 90 | issue = 6 | pages = 321–30 |date=December 1987 | pmid = 3443414 | doi = 10.1254/fpj.90.321| doi-access = free }}{{cite journal |vauthors=Anami K, Setoguchi M, Senoh H | title = [Pharmacological studies on Y-8894. (VIII). Effects on learning and memory in the radial maze task in mice] | language = ja | journal = Nihon Yakurigaku Zasshi. Folia Pharmacologica Japonica | volume = 92 | issue = 2 | pages = 113–8 |date=August 1988 | pmid = 3224898 | doi = 10.1254/fpj.92.113| doi-access = free }} it was ultimately developed and approved as an antidepressant instead.{{cite journal |vauthors=Ogura C, Kishimoto A, Kunimoto N, etal | title = Clinical pharmacology of a new antidepressant, Y-8894 in healthy young and elderly volunteers | journal = British Journal of Clinical Pharmacology | volume = 23 | issue = 5 | pages = 537–43 |date=May 1987 | pmid = 3593624 | pmc = 1386189 | doi = 10.1111/j.1365-2125.1987.tb03089.x}} It acts as a potent norepinephrine reuptake inhibitor, with fair selectivity over the serotonin and dopamine transporters, and also behaves as an antagonist of the 5-HT_2A receptor.{{cite patent|country=JP|number=2008189616A | title=Therapeutic Agent for Attention-Deficit Hyperactivity Disorder }}